Forimtamig Shows Deep, Durable Responses in Relapsed/Refractory Multiple Myeloma
September 29th 2023At a median duration of response of 12.2 months, the objective response rates with forimtamig across all dose levels was 66.7% with a very good partial response rate of 54.2%, according to data from a phase 1a dose-escalation trial.
Read More
Real-World Study of Teclistamab Matches MajesTec-1 Efficacy Data in RRMM
September 29th 2023According to data presented at IMS 2023, a real-world analysis showed that teclistamab demonstrated comparable efficacy to the results observed in the phase 2 MajesTec-1 trial for patients with relapsed/refractory multiple myeloma.
Read More
Safety/Efficacy of Dara-KRd and Double Transplant Confirmed in Newly Diagnosed Myeloma
September 29th 2023The Dara-KRd regimen with double transplant induced deep response rates and a high minimal residual disease negativity rates among patients with high-risk, newly diagnosed multiple myeloma.
Read More
CAR T Cells and Bispecifics Generate Excitement in Multiple Myeloma
September 29th 2023Madhav V. Dhodapkar, MBBS, discusses some of the immunotherapies under investigation and those that are being highlighted at the 20th International Myeloma Society Annual Meeting for patients with multiple myeloma.
Watch
Furmonertinib Shows Encouraging Efficacy in EGFR Exon20Ins Mut+ NSCLC
September 10th 2023According to Baohui Han, MD, PhD, the confirmed objective response rate was 78.6% for treatment-naïve patients with non–small cell lung cancer with EGFR Exon20 insertion mutations treated with furmonertinib 240 mg daily in the FAVOUR trial.
Read More
Quizartinib Improves OS in Multiple FLT3-ITD+ AML Subgroups
September 9th 2023According to a presentation at SOHO 2023, overall survival was boosted among patients from the QuANTUM-First trial who went to transplant in first remission and were treated with quizartinib for their FLT3-ITD-positive acute myeloid leukemia.
Read More
CAR T-Cell Therapy Access Remains Elusive, But Solutions May Be Closer Than Expected
September 9th 2023Widespread access to CAR T-cell therapy remains a problem, and quite a few challenges have arisen in regards to optimizing outcomes for CAR T-cell therapy in patients with hematologic malignancies and solid tumors.
Read More
Exploring Novel Combinations in Indolent Lymphomas
September 9th 2023Although chemotherapy has represented the standard therapeutic modality for indolent non-Hodgkin lymphoma, monoclonal antibodies, immunomodulatory agents, targeted agents, bispecific antibodies, and cellular therapies are now available.
Read More
Fixed-Duration Loncastuximab Tesirine May Be Beneficial Earlier on in R/R DLBCL Treatment
September 8th 2023Relapsed/refractory DLBCL is associated with poor prognosis, but preclinical data suggest that adding rituximab to CD19-directed therapy such as loncastuximab tesirine may extend the duration of disease control.
Read More